To test the efficacy of warfarin in the secondary prevention of non-embolic stroke among patients with atrial fibrillation.
- Warfarin (Coumadin®)Drug
Intervention Desc: Anticoagulant (Vitamin K antagonist)
Controlled trial of 386 patients.
Patients with atrial fibrillation were characterized for stroke subtype on clinical, neuroimaging, carotid ultrasonographic and echocardiographic criteria. Eligible patients were treated with adjusted dose warfarin (INR 2.0-3.0). Aspirin (75-300 mg daily) was used in patients with contraindications or refusing anticoagulation. Patients were followed for 2 years.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Rate of recurrent stroke and minor bleeding complications.|